ArticleScientific reports2026
Characterization of Alternaria alternata alternariol monomethyl ether with a potential antiproliferative activity by topoisomerases inhibition; molecular docking and dynamic simulations.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioprocessing of monomethyl ether from Alternaria alternata, a multi-target antiproliferative compound as emphasized by in silico analysis.Scientific reports · 2026Article
- Green synthesis of tetrahydropyridine-3-carboxylate derivatives and evaluation of antimicrobial and antimalarial activities supported by molecular docking, POM studies, and drug-likeness analysis.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The drug resistance is one of the challenges in cancer chemotherapy, due to the development of different drug-efflux pumps that expels the drug out of the cells, thus, searching for new compounds with multiple targets in tumor cells, could be an affordable chemotherapy. Alternariol monomethyl ether (AME) was preliminary recognized as a cytotoxic compound, however, its availability and equivocal activity are the hurdles for further applications. Alternaria alternata EFBL-025, PV342518.1, endophyte of Catharanthus roseus, exhibited the highest AME productivity (550 μg/l). Chemically, the structure of putative compound of A. alternata was committed from the TLC, HPLC and LC-MS/MS, with molecular mass 274.2 m/z, and typical fragmentation pattern of authentic AME. The purified AME of A. alternata exhibited a substantial activity against the MCF-7 (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.